Latest news with #Mounjaro
Newsweek
5 hours ago
- Health
- Newsweek
Men Are Gaining More Confidence From Ozempic Than Women: Report
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. While some may associate Ozempic and other GLP-1 medications with women trying to lose weight, it turns out that men are the ones gaining the most significant confidence boosts from it. In a Kinsey Institute and survey of GLP-1 users, men were three times more likely than women to say GLP-1s gave them more confidence. They also experienced more notable improvements in their dating lives and libidos. Why It Matters In recent years, the use of weight-loss medications called glucagon-like peptide-1 (GLP-1) receptor agonists has surged. Popular products include Ozempic, Mounjaro, Wegovy and Zephound and have been a game changer for many Americans who are obese or have type 2 diabetes. For patients who successfully lose weight, there can be significant changes in their mental health as well as their personal dating lives, but this impact appears to be more pronounced among male users. Ozempic is medicine for adults with type 2 diabetes. Wegovy is prescribed for long-term weight loss in adults and children. Both contain the active ingredient semaglutide, on January 13, 2025, in Sydney, Australia. Ozempic is medicine for adults with type 2 diabetes. Wegovy is prescribed for long-term weight loss in adults and children. Both contain the active ingredient semaglutide, on January 13, 2025, in Sydney, Australia. Steve Christo - Corbis/Corbis via Getty Images What To Know Across the entire survey sample, drugs like Ozempic were having major effects on users' dating lives. While 59 percent of users said the drugs changed their dating experiences, men experienced a more notable impact on their confidence levels and sex lives, according to the report. Men were three times more likely than women to say GLP-1s boosted their confidence and two times more likely to say they were going on more dates. They also reported higher libido, more matches and increased sexual activity. Still, there were some negative implications for men, of which 60 percent said they feared being judged for using GLP-1s and worried they'd be seen as "less masculine" for doing so. Of all GLP-1 users surveyed, 12 percent said they were going on more dates, and 14 percent said they were getting more matches on dating apps. Meanwhile, a whopping 52 percent reported changes in their sex lives. What People Are Saying Dr. Justin Lehmiller, the Kinsey Institute study lead, said in a statement: "I think there's a very nuanced story to tell here. How these drugs impact your sex life will depend on a variety of factors, including drug dosage and drug type, speed of weight loss, starting and ending weight, and how much you changed your health and fitness habits at the same time." "Sexually speaking, it appears that men are experiencing more positive and more negative impacts of GLP-1 medications." What Happens Next The long-term implications of GLP-1 medication use are so far unclear. A recent study discovered a new link between taking GLP-1 drugs and elevated risk of pancreatitis and kidney conditions, including kidney stones. GLP-1 medications are also associated with a higher risk of digestive problems, including nausea, vomiting, diarrhea, and even stomach paralysis in rare cases.
Economic Times
7 hours ago
- Health
- Economic Times
ET Graphics: Weight loss drugs Tirzepatide, Semaglutide dominate India, misuse fears rise
Tirzepatide and semaglutide dominate India's anti-obesity drug market, holding a 75% share. While seen as vital tools by doctors, experts caution against misuse, particularly among young adults. Aggressive marketing and social media trends are fueling peer pressure, potentially leading to inappropriate use of these weight-loss medications. Tired of too many ads? Remove Ads New-age weight-loss molecules have taken over the anti-obesity drug market in India , with tirzepatide and semaglutide (generic names) collectively occupying 75% of the market see Eli Lilly's Mounjaro and Novo Nordisk's Wegovy as important ammunitions in the anti-obesity experts also point out the risk of the drug being misused by many — especially young adults — amplied by aggressive marketing, widespread social media promotions and a growing peer pressure driven by the weight loss fad.
Time of India
8 hours ago
- Health
- Time of India
ET Graphics: Weight loss drugs Tirzepatide, Semaglutide dominate India, misuse fears rise
New-age weight-loss molecules have taken over the anti-obesity drug market in India , with tirzepatide and semaglutide (generic names) collectively occupying 75% of the market share. Doctors see Eli Lilly's Mounjaro and Novo Nordisk's Wegovy as important ammunitions in the anti-obesity treatment. However, experts also point out the risk of the drug being misused by many — especially young adults — amplied by aggressive marketing, widespread social media promotions and a growing peer pressure driven by the weight loss fad. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Discover Effortless Glucose Monitoring: Request a Free Trial Dexcom Click Here Undo
Yahoo
8 hours ago
- Health
- Yahoo
Weight loss jabs such as Mounjaro linked to lower dementia and stroke risk
Weight loss jabs may offer a protective effect against dementia and stroke, according to a new study. Academics said the benefits of drugs such as Wegovy and Mounjaro – including for managing weight and blood sugar levels – are well known, but other health benefits of the popular drugs remain 'unclear'. People with type 2 diabetes and obesity who are taking the drugs are also less likely to die prematurely, researchers found. The study saw experts from Taiwan examine date on 60,000 people from around the world, with an average age of 58, who had type 2 diabetes and obesity. Key differences between three weight-loss injections: Mounjaro, Wegovy, and Ozempic. — Paul Wischmeyer MD (@Paul_Wischmeyer) July 4, 2025 Around half were given GLP agonist drugs semaglutide and tirzepatide – which are sold under the brand names Wegovy and Mounjaro. Semaglutide is also the main ingredient for the type 2 diabetes drug Ozempic. GLP agonists can reduce a person's appetite; slow down their digestion; reduce the amount of sugar the liver makes and they help the body to make more insulin when needed. The other half used other anti-diabetic medication. 📢Important update Eligible people in #Dorset will be able to access Tirzepatide (Mounjaro) weight management medication from autumn 2025. ✅Around 1,000 people in Dorset will qualify under strict national criteria ✅No need to contact your doctor More: — NHS Dorset (@NHSDorset) June 23, 2025 During a seven-year follow-up period, researchers found that people given the GLP agonist drugs appeared to have a 37% lower risk of dementia and a 19% reduced risk of stroke. They were also 30% less likely to die during the follow-up period. And when researchers looked at the data further they found even greater benefits in people aged 60 or older, women, and those with a body mass index score of 30 to 40. They found no differences in Parkinson's disease or brain bleeds. The academics said their findings suggest 'potential neuroprotective and cerebrovascular benefits' of the drugs but they called for more studies to confirm the findings. Recommended reading: Mounjaro sales adverts banned by watchdog Mounjaro patients report unexpected side-effect Who is eligible for free Mounjaro on the NHS? 'These findings suggest that semaglutide and tirzepatide may offer neuroprotective and cerebrovascular benefits beyond glycemic control, potentially improving long-term cognitive and survival outcomes in adults with type 2 diabetes and obesity,' they wrote in the journal JAMA Network Open. Commenting on the study, Professor Tara Spires-Jones, director of the Centre for Discovery Brain Sciences at the University of Edinburgh and group leader in the UK Dementia Research Institute, said: 'This is a very interesting study adding to evidence that GLP1 receptor agonists are associated with a lower risk of dementia in people with type 2 diabetes and obesity. 'This type of study cannot determine whether the drugs reduced disease risk by directly protecting the brain. 'It is highly likely that effectively treating type 2 diabetes and obesity would reduce dementia and stroke risk as they are known risk factors for these conditions. 'Further work is needed including randomised clinical trials to confirm these drugs are protective in people with diabetes and obesity and other trials are needed to determine whether these drugs will be protective in people who do not have type 2 diabetes and obesity.' Recommended reading: When will Mounjaro be rolled out on the NHS? Travel insurance warning about certain types of policy Warning as Mounjaro and Ozempic sold without prescription Dr Richard Oakley, associate director of research and innovation at Alzheimer's Society, said: 'It is well established that diabetes and obesity can increase your risk of developing dementia. 'This study supports existing evidence that shows these drugs may reduce dementia risk, particularly for people aged 60 and over who are living with type 2 diabetes and obesity. 'Although interesting, we can't draw conclusions from this study alone as it is an observational study, only a small number of people who took part went on to develop dementia and as the impact of these drugs on different types of dementia is not clear. 'There are clinical trials currently looking at whether drugs like these can be used to treat early-stage Alzheimer's disease, so this is a really exciting area being explored in the research fight against dementia.'
The Independent
9 hours ago
- Health
- The Independent
How weight-loss jabs could help lower dementia risk
New research indicates that weight-loss injections, including popular drugs like Wegovy and Mounjaro, may offer protection against serious conditions such as dementia and stroke. The study also suggests that individuals with type 2 diabetes and obesity prescribed these medications could face a reduced risk of premature death. Experts from Taiwan conducted a comprehensive study, examining data from 60,000 people worldwide with an average age of 58, all diagnosed with type 2 diabetes and obesity. During a seven-year follow-up, participants given GLP agonist drugs showed a 37 per cent lower risk of dementia, a 19 per cent reduced risk of stroke, and were 30 per cent less likely to die. Academics noted potential neuroprotective and cerebrovascular benefits but called for more studies, including randomised clinical trials, to confirm these findings.
